Nasdaq
$1.61▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.0MShares out 1.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 1d agoAfter-hours26.10.24 05:058-KKey event#●●●
Aptevo Therapeutics Inc.
Aptevo Therapeutics has extended the expiration date of its 2020 Rights Agreement (poison pill) to October 23, 2027. Additionally, the company adjusted the purchase price of its Series A Junior Participating Preferred Stock from $70 to $14.56 per one one-thousandth of a share.…more
$1.61+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 21:528-KKey event
Aptevo Therapeutics Inc.
Aptevo Therapeutics will present its multispecific platform technology at the SITC 2026 Annual Meeting, scheduled for November 4–8, 2026. The presentation will highlight the company's CD40-directed multispecific portfolio and its approach to coordinating innate and adaptive immune activity within the tumor microenvironment.…more
$1.61+0.00%vs prev closeView filingShare - 9.25After-hours26.09.26 05:05S-8Offering
Aptevo Therapeutics Inc.
Aptevo Therapeutics has filed a Form S-8 registration statement to register an additional 325,000 shares of common stock under its Fourth and Fifth Amended 2018 Stock Incentive Plans. This action follows shareholder approval at the annual and special meetings held on August 21 and September 22, 2026, respectively. The company's financial reports continue to include an explanatory paragraph regarding uncertainty about its ability to continue as a going concern.…more
$1.61+0.00%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Pre-market26.09.24 21:13#●●●#●●●
Aptevo Targets 2027 for IND-Enabling Studies of APVO451
Aptevo Therapeutics plans to initiate IND-enabling studies for its lead trispecific cancer candidate, APVO451, in the first half of 2027. The company is currently focusing on optimizing manufacturing processes to support future clinical testing and reduce development risks.…more
$1.61+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.3Regular26.09.04 03:25
●●●●●●●● ●●●●● ●●●●●●
Aptevo Therapeutics announced a 93% clinical benefit rate for its leukemia drug candidate in a recent trial. Despite the positive clinical data, the company's stock price experienced a significant decline.…more
$1.61+0.00%vs prev closeShareBenzinga - 9.3Pre-market26.09.03 21:10
●●●●●●●● ●●●●● ●●●●●●
Aptevo's Mipletamig triplet therapy achieved a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations. These results nearly double the remission outcomes compared to previously published data for standard treatments.…more
$1.61+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report